Drug response can be impacted by multiple factors, including pharmacodynamics and pharmacokinetics
The PGxOne™ Plus report provides biological systems-based recommendations with test results accounting for medications being influenced by multiple genetic variants, first individually and then in one combined patient impact statement.
Biological Systems Based results across multiple therapeutic areas are organized with rapid implementation in mind
Test results include specific sections for Current Medications and Medications of Interests followed by a comprehensive sections. Results are organized alphabetically by therapeutic area, drug class, and mechanism of action.
The PGxOne™ Plus test combines with RxVision™, a dynamic online reporting tool, to provide a complete PGx assessment
High-integrity gene-drug interactions align with sources from the FDA with additional PGx information available in RxVision that is sourced from the FDA, Clinical Pharmacogenetics Implementation Consortium (CPIC), Association for Molecular Pathologists (AMP), and the College of American Pathologist (CAP).